Skip to main content

and
  1. Article

    Open Access

    Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

    No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests bu...

    Nicolette M. Fonseca, Corinne Maurice-Dror, Cameron Herberts in Nature Communications (2024)

  2. No Access

    Article

    Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genoty**

    De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical in...

    Evan W. Warner, Kim Van der Eecken, Andrew J. Murtha, Edmond M. Kwan in Nature Cancer (2024)

  3. Article

    Open Access

    Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer

    Molecular stratification can improve the management of advanced cancers, but requires relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a recent expansion of treatment op...

    Gillian Vandekerkhove, Jean-Michel Lavoie, Matti Annala in Nature Communications (2021)